More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$30.63B
EPS
5.81
P/E ratio
51.9
Price to sales
9.35
Dividend yield
--
Beta
1.46574
Previous close
$198
Today's open
$199.73
Day's range
$196.61 - $203.11
52 week range
$112.65 - $309.35
show more
CEO
Jacob Thaysen
Employees
8600
Headquarters
San Diego, CA
Exchange
Nasdaq Global Select
Shares outstanding
151200000
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Diamond Hill Mid Cap Strategy Q3 2026 Portfolio Review
The Strategy declined 3.83% (net of fees) and the Russell Midcap Index declined 3.00%. Key contributors include Illumina, Revvity and Waystar. Key detractors include Regal Rexnord, Rocket Companies and Red Rock Resorts.
Seeking Alpha • 16 hours ago

Illumina Sees Strong Clinical Demand, but Research Recovery Remains in Question
Illumina NASDAQ: ILMN is seeing strong demand for its sequencing instruments from clinical customers, while remaining cautious about a recovery in research spending, Chief Financial Officer Ankur Dhingra said at a company news event.
MarketBeat • Nov 17, 2026

Illumina, Inc. (ILMN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Illumina, Inc. (ILMN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • Nov 17, 2026

Thrivent Mid Cap Stock Fund Q3 2026 Performance Review
Thrivent Mid Cap Stock Fund returned (2.92%) versus the Russell Mid Cap Index's (3.00%) return. Top contributors include Veeva Systems, Illumina and Zebra Tech. Top detractors include RH and UL Solutions.
Seeking Alpha • Nov 17, 2026

Illumina Bets on Clinical Demand for Growth as Research Funding Uncertainty Persists
Illumina NASDAQ: ILMN expects clinical demand and sequencing consumables to remain central to its growth strategy, even as research customers continue to face uncertainty over grant funding, executives said at a UBS discussion.
MarketBeat • Nov 11, 2026

Illumina, Inc. (ILMN) Presents at 2026 UBS Global Healthcare Conference Transcript
Illumina, Inc. (ILMN) Presents at 2026 UBS Global Healthcare Conference Transcript
Seeking Alpha • Nov 10, 2026

Illumina advances MRD research portfolio with ultrasensitive duplex sequencing technology
Early access program launches to support ultrasensitive research into molecular residual disease and tumor evolution. New chemistry is optimized for highest possible accuracy, with reproducible detection of ctDNA at 2.5 parts per million levels with low sample input (10 nanograms) in representative studies SAN DIEGO, Nov. 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced an expansion of its molecular residual disease (MRD) research portfolio with an early access program for an ultrasensitive sequencing workflow.
PRNewsWire • Nov 9, 2026

REGN vs. ILMN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Regeneron (REGN) and Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?
Zacks Investment Research • Nov 4, 2026

Illumina selected to help bring precision medicine into everyday healthcare in Singapore
SG-INSIGHT study will extend whole-genome sequencing to nearly 1 in 10 Singapore residents, generating evidence to inform how precision medicine could be implemented in Singapore's healthcare system SINGAPORE, Nov. 2, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) today announced it has been selected to provide whole-genome sequencing services for the SG-INSIGHT study, a cohort under Phase III of Singapore's National Precision Medicine (NPM) programme. Expected to include approximately one in 10 Singapore residents, or around 450,000 individuals, the study is designed to generate evidence from genomic and health data to help inform preventive approaches to healthcare.
PRNewsWire • Nov 3, 2026

Don't Overlook Illumina (ILMN) International Revenue Trends While Assessing the Stock
Explore Illumina's (ILMN) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Zacks Investment Research • Nov 2, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Illumina Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.